JNJ
190.6
-0.77%↓
ABT
126.77
+0.33%↑
MDT
93.77
-0.45%↓
VEEV
293.21
+0.68%↑
A
148.21
+0.39%↑
JNJ
190.6
-0.77%↓
ABT
126.77
+0.33%↑
MDT
93.77
-0.45%↓
VEEV
293.21
+0.68%↑
A
148.21
+0.39%↑
JNJ
190.6
-0.77%↓
ABT
126.77
+0.33%↑
MDT
93.77
-0.45%↓
VEEV
293.21
+0.68%↑
A
148.21
+0.39%↑
JNJ
190.6
-0.77%↓
ABT
126.77
+0.33%↑
MDT
93.77
-0.45%↓
VEEV
293.21
+0.68%↑
A
148.21
+0.39%↑
JNJ
190.6
-0.77%↓
ABT
126.77
+0.33%↑
MDT
93.77
-0.45%↓
VEEV
293.21
+0.68%↑
A
148.21
+0.39%↑
24u
Huidig
Min
4.02
Max
4.22
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +170.27% upside |
Volgende Winsten | 31 okt 2025 |
|---|
By Acuity
81%
19%
344 / 371 Rangschikking in Healthcare
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
24 okt 2025, 13:04 UTC
Eli Lilly Agrees to Acquire Adverum Biotechnologies
DJ
Lezen
24 okt 2025, 12:34 UTC
Eli Lilly Says Transaction Is Expected to Close in the 4Q >LLY
DJ
Lezen
24 okt 2025, 12:34 UTC
Eli Lilly: Offer Also Includes 1 Non-Transferrable Contingent Value Right Entitling Holder to Receive Up to an Additional $8.91 Per CVR in Cash Upon the Achievement of 2 Milestones, for Total Potential Consideration of Up to $12.47/Shr >LLY
DJ
Lezen
24 okt 2025, 12:33 UTC
Eli Lilly to Launch Tender Offer to Acquire All Outstanding Shares of Adverum for $3.56/Shr >LLY
DJ
Lezen
24 okt 2025, 12:30 UTC
Lilly To Acquire Adverum Biotechnologies >LLY ADVM
DJ
Lezen
Prijswijziging
By TipRanks
12 Maanden Prognose
Gemiddelde 11 USD 170.27%
Hoogste 30 USD
Laagste 3 USD
Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Adverum Biotechnologies Inc - Dist. in de afgelopen 3 maanden.
By TipRanks
Buy
6 ratings
3
Buy
3
Hold
0
Sell
Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Adverum Biotechnologies Inc - Dist in de afgelopen 3 maanden.
By Acuity
Nieuwssentiment
Zeer Sterk Bearish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Boven gemiddelde
$